Isofol Medical AB (publ) is a pioneering brand dedicated to enhancing the effectiveness of current standard treatments for colorectal cancer and other tumor diseases. The company is focused on developing the drug candidate arfolitixorin, which has shown promise in increasing the efficacy of existing therapies. Isofol Medical has completed a Phase III study for arfolitixorin and is now evaluating opportunities to move forward with a marketing authorization application by conducting additional studies and exploring potential partnerships.

As colorectal cancer is the third most common form of cancer globally, there is a critical need for more effective treatment options. Isofol Medical AB (publ) is traded on Nasdaq Stockholm, further illustrating its commitment to innovation and growth in the medical field